Solid Coated Carrier Immobilizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases using systemic monoclonal antibodies are expensive and associated with severe side effects due to ill-defined fate and immune reactions, while existing devices for immobilized antibodies are cumbersome and costly to implement.
Innovation Solution
A method of producing a solid coated carrier by incubating a solid carrier with a solution containing couplers like diaminoalkanes or polyethyleneglycol, attaching antibodies, and embedding them in a matrix with substances like peptides and sugars to create a stable, sterile device for therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic monoclonal antibodies are administered to treat diseases, then therapeutic effects are achieved, but severe side effects and high costs occur due to immune reactions and ill-defined fate
Solution Approach 1:
The patent extracts the therapeutic function of monoclonal antibodies from systemic circulation and relocates it to an immobilized state on a solid carrier surface. This separation allows the antibody to exert its therapeutic effect locally without being distributed systemically, thereby eliminating immune reactions and side effects associated with systemic administration while maintaining therapeutic efficacy
Solution Approach 2:
The patent introduces a solid carrier as an intermediary between the antibody and the biological environment. The carrier surface serves as a mediator that holds the antibody in a controlled, immobilized state, enabling therapeutic action without direct systemic introduction of the antibody, thus avoiding harmful immune responses
2Reliability
If devices with immobilized antibodies are used to avoid systemic side effects, then therapeutic safety improves, but device complexity and implementation burden increase
Solution Approach 1:
The patent modifies the physical state of the antibody from soluble/systemic to immobilized/surface-bound by changing its spatial configuration and interaction parameters with the carrier surface. This parameter change enables the antibody to function therapeutically in a simplified device format without requiring complex systemic delivery mechanisms, reducing implementation burden while maintaining safety
Solution Approach 2:
The patent creates a localized therapeutic environment by immobilizing antibodies on a solid carrier surface with specific properties. The carrier surface provides a defined local environment that concentrates therapeutic activity at the site of need without requiring complex systemic distribution mechanisms, thereby simplifying device implementation while ensuring therapeutic safety
3Object-affected harmful factors
If antibodies are immobilized on a solid carrier, then side effects are minimized, but manufacturing complexity increases due to multiple coating and treatment steps
Solution Approach 1:
The patent applies preliminary coating steps to the solid carrier surface before antibody immobilization, including application of couplers and blocking agents. These preliminary actions prepare the surface in advance to ensure optimal antibody binding and prevent non-specific interactions, thereby minimizing side effects while establishing a standardized manufacturing protocol that can be replicated
4Manufacturing precision
If multiple coating steps are applied to the solid carrier, then manufacturing precision improves, but production time and complexity increase
Solution Approach 1:
The patent employs periodic, sequential coating steps with defined intervals and conditions for each layer application. This periodic approach allows each coating layer to be applied, dried, and stabilized in sequence, ensuring manufacturing precision and uniformity while maintaining an efficient production rhythm that minimizes total production time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of stable, sterile solid coated carriers that minimize side effects by immobilizing biological materials, allowing for defined therapeutic or diagnostic impacts without releasing the materials into the body fluid, thus improving treatment efficiency and stability.
Implementation Method 1
incubating a solid carrier with a solution comprising 0.1 to 10 % (w/w) or (v/v) of at least one suitable coupler... thereby attaching a layer of the at least one suitable coupler to the carrier
Implementation Method 2
incubating the carrier in a buffered aqueous solution containing a blocking agent... blocking unbound binding sites
Implementation Method 3
incubating the carrier in an aqueous solution comprising one or more substances selected from polypeptides, at least one amino acid... such that the antibody is partially or completely covered by said one or more substances
Data Source
Figure 1
Figure 2A~2D
Figure 3
AI summary
The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coated carrier for the preparation of a medical product. Moreover, the invention provides a method for the contacting, filtration or cleaning of blood, lymph or liquor cerebrospinalis of a patient, a method for the diagnosis of a disease and a diagnostic composition.